Home›Sofosbuvir›Sofosbuvir + Lamivudine And Tenofovir Disoproxil Fumarate

Does Sofosbuvir Interact with Lamivudine And Tenofovir Disoproxil Fumarate?

CDI records a moderate classification for Sofosbuvir and Lamivudine And Tenofovir Disoproxil Fumarate. The stored summary is: 7.3 Hepatitis C Antiviral Agents Coadministration of TDF, a component of CIMDUO, and EPCLUSA ® (sofosbuvir/velpatasvir) or HARVONI ® (ledipasvir/sofosbuvir) has been shown to increase tenofovir exposure [see Clinical Pharmacology (12.3) ] . In patients receiving TDF concomitantly with sofosbuvir/velpatasvir, monitor for adverse reactions associated with TDF. In patients receiving CIMDUO concomitantly with ledipasvir/sofosbuvir without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, monitor for adverse reactions associated with tenofovir. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Sofosbuvir Class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Lamivudine And Tenofovir Disoproxil Fumarate Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Sofosbuvir and your doctor is considering prescribing Lamivudine And Tenofovir Disoproxil Fumarate (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Sofosbuvir(Sovaldi)+💊 Lamivudine And Tenofovir Disoproxil Fumarate(Cimduo)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Drug B class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Source
FDA drug label - lamivudine and tenofovir disoproxil fumarate

What this means in plain English

7.3 Hepatitis C Antiviral Agents Coadministration of TDF, a component of CIMDUO, and EPCLUSA ® (sofosbuvir/velpatasvir) or HARVONI ® (ledipasvir/sofosbuvir) has been shown to increase tenofovir exposure [see Clinical Pharmacology (12.3) ] . In patients receiving TDF concomitantly with sofosbuvir/velpatasvir, monitor for adverse reactions associated with TDF. In patients receiving CIMDUO concomitantly with ledipasvir/sofosbuvir without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, monitor for adverse reactions associated with tenofovir.

About Sofosbuvir and Lamivudine And Tenofovir Disoproxil Fumarate

Sofosbuvir is a Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor, while Lamivudine And Tenofovir Disoproxil Fumarate is a Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor. You may recognize them by the brand names Sovaldi and Cimduo. Both Sofosbuvir and Lamivudine And Tenofovir Disoproxil Fumarate carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - lamivudine and tenofovir disoproxil fumarate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Sofosbuvir and Lamivudine And Tenofovir Disoproxil Fumarate against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations